论文部分内容阅读
目的:探讨长期瑞舒伐他汀治疗对冠状动脉慢血流患者冠脉贮备功能(CFR)和超敏C反应蛋白(hsCRP)的影响。方法:选择冠状动脉造影正常但存在冠脉慢血流的患者48例,所有患者随机分为试药组和对照组,对照组(22例)予常规治疗,试药组(26例)在常规治疗基础上加用瑞舒伐他汀20 mg/d,治疗期为6个月。治疗前后测定两组患者的血脂,hsCRP,利用腺苷负荷超声记录左前降支远端血流频谱评评价CFR。结果:经过6个月瑞舒伐他汀的治疗后,试药组总胆固醇(TC)和低密度脂蛋白胆固醇(LDL-C)较对照组明显下降,[TC:(3.2±0.9)mmol/Lvs.(5.4±1.2)mmol/L,P<0.05;LDL-C:(2.1±0.7)mmol/L vs.(3.4±0.8)mmol/L,P<0.05]。hsCRP较对照组明显下降[(2.1±1.4)mg/L vs.(3.7±2.1)mg/L,P<0.05]。试药组静息冠脉血流速度(bCFV)较对照组和治疗前显著下降[(21±6)cm/s vs.(26±5)cm/s和(21±6)cm/s vs.(25±7)cm/s,P<0.05],而最大冠状动脉扩张状态hCFV较对照组和治疗前增加[(71±9)cm/s vs.(56±8)cm/s和(71±9)cm/s vs.(56±10)cm/s,P<0.05],冠状动脉血流储备CFR较对照组和治疗前明显增加[(3.2±0.6)cm/s vs.(2.1±0.5)cm/s和(3.2±0.6)cm/s vs.(2.2±0.4)cm/s,P<0.05)]。结论:冠状动脉慢血流患者经过瑞舒伐他汀治疗可以有效改善冠脉贮备功能。
Objective: To investigate the effects of long-term rosuvastatin on coronary artery reserve function (CFR) and hsCRP in patients with coronary arterial slow flow. Methods: Forty-eight patients with normal coronary arteries and slow blood flow of coronary arteries were selected. All patients were randomly divided into two groups: control group (n = 22) and control group (n = 22) Treatment based on the use of rosuvastatin 20 mg / d, the treatment period of 6 months. Serum lipids and hsCRP were measured in two groups before and after treatment. CFR was evaluated by recording the distal left anterior descending artery blood flow using adenosine stress. Results: After six months of treatment with rosuvastatin, total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) in the test group were significantly lower than those in the control group [TC: (3.2 ± 0.9) mmol / L vs (5.4 ± 1.2) mmol / L, P <0.05; LDL-C: (2.1 ± 0.7) mmol / L vs. (3.4 ± 0.8) mmol / L, P <0.05]. hsCRP decreased significantly compared with the control group [(2.1 ± 1.4) mg / L vs. (3.7 ± 2.1) mg / L, P <0.05]. Resting coronary flow velocity (bCFV) in the test group was significantly lower than that in the control group and before treatment [(21 ± 6) cm / s vs. (26 ± 5) cm / s and (21 ± 6) cm / s vs (25 ± 7) cm / s, P <0.05], while the maximum coronary artery dilatation hCFV was significantly higher than that of the control group and before treatment (71 ± 9 cm / s vs. 56 ± 8 cm / (3.2 ± 0.6) cm / s vs. (2.1 ± 0.9) cm / s vs (56 ± 10) cm / s, P <0.05]. The CFR of coronary flow reserve was significantly higher than that of the control group and before treatment ± 0.5 cm / s and (3.2 ± 0.6) cm / s vs. (2.2 ± 0.4) cm / s, P <0.05)]. Conclusion: Coronary artery slow flow patients after rosuvastatin treatment can effectively improve coronary reserve function.